ENTA: SEC Form 10-K filed by Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc. has filed its annual 10-K report for the fiscal year ended September 30, 2026. The report focuses on regulatory background and their lead candidate, EPS-5336, a MRGPRX2 inhibitor, which is in IND-enabling work with an IND filing targeted for Q4 2027. The provided excerpt does not include financial results, requiring shareholders to consult the full filing for performance details.
ENTA: SEC Form 10-K filed by Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals has filed its annual 10-K report for the fiscal year ending September 30, 2026. The report details the lead candidate EPS-5336, a MRGPRX2 inhibitor in IND-enabling work, with an IND filing targeted for Q4 2027. The provided excerpt does not include new financial results, necessitating review of the full filing for a comprehensive performance assessment.
Enanta Pharma Q4 Results: Loss widens to $0.81 per share, revenue down 14.92%
Enanta Pharmaceuticals reported a wider-than-expected Q4 loss of $(0.81) per share, missing analyst estimates of $(0.78). Quarterly revenue also declined by 14.92% year-over-year to $12.868 million, falling short of the $14.200 million forecast. Despite a slight improvement in loss per share from the prior year, the significant revenue contraction indicates that cost efficiencies were insufficient to offset the drop in sales.
ENANTA PHARMACEUTICALS ($ENTA) Releases Q4 2026 Earnings, Stock Rises
ENANTA PHARMACEUTICALS (ENTA) reported its Q4 2026 earnings, missing analyst estimates for both earnings per share and revenue. Despite the miss, the company's stock price saw a 2.5% increase since market close. The article also details recent hedge fund activity and analyst ratings for the company.
Enanta earnings missed by $0.04, revenue fell short of estimates
Enanta (NASDAQ: ENTA) reported its fourth-quarter earnings, missing analyst estimates for EPS by $0.04 with a reported $-0.81, and falling short on revenue with $12.86M against an expected $15.7M. The company's stock price closed at $10.67, experiencing declines of -18.74% over the last three months and -16.77% over the past year.
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
Enanta Pharmaceuticals (ENTA) reported a Q4 loss of $0.81 per share, which was narrower than the Zacks Consensus Estimate of a $0.83 loss, but missed revenue estimates with $12.87 million against an expected $14.39 million. The company's shares have declined significantly year-to-date, underperforming the S&P 500, and currently hold a Zacks Rank #3 (Hold) indicating expected in-line market performance.
Enanta Pharmaceuticals Announces CEO Retirement and COO Appointment
Enanta Pharmaceuticals announced that its longtime President and CEO, Jay R. Luly, will retire by February 1, 2027, after 23 years with the company, and will remain as a strategic advisor through 2027. Concurrently, Tara L. Kieffer has been appointed to the newly created role of Chief Operating Officer to enhance operational execution. The company is actively searching for a successor to guide its next phase of growth and pipeline advancement.
Enanta Pharmaceuticals CEO Jay R. Luly to Retire in February 2027 After 23 Years; Tara Kieffer Named COO
Jay R. Luly, President and CEO of Enanta Pharmaceuticals (NASDAQ: ENTA), will retire by February 1, 2027, after 23 years with the company and a 43-year career in pharmaceuticals. Enanta's board has started a search for his successor, and Luly will remain as a strategic advisor throughout 2027 to support the transition. Additionally, Tara L. Kieffer, Ph.D., has been appointed Chief Operating Officer, a newly created role to enhance operational execution as the company continues to develop small-molecule therapies for viral infections and immunological diseases.
Form 8K Enanta Pharmaceuticals Inc For: 28 October By Investing.com
Enanta Pharmaceuticals Inc. filed a Form 8K for October 28, 2026. The article from Investing.com provides this brief financial news without further details on the filing's content. It also includes general market data and other popular articles.
Form 8K Enanta Pharmaceuticals Inc For: 28 October By Investing.com
This article announces that Enanta Pharmaceuticals Inc. has filed a Form 8K for October 28. It is a brief notification from Investing.com, providing only the filing information and the company's stock ticker (ENTA).
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership
Enanta Pharmaceuticals announced that its President and CEO, Jay R. Luly, Ph.D., will retire by February 1, 2027, after 23 years of leadership, and will serve as a Strategic Advisor for the remainder of 2027. The company has also appointed Tara L. Kieffer, Ph.D., as the new Chief Operating Officer. Enanta's Board of Directors has initiated a search for Dr. Luly's successor to guide the company's next phase of growth.
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership
Enanta Pharmaceuticals (NASDAQ:ENTA) announced that its President and CEO, Jay R. Luly, Ph.D., will retire by February 1, 2027, after 23 years of leadership. Dr. Luly will continue as a Strategic Advisor for the remainder of 2027 to ensure a smooth transition. The company has also appointed Tara L. Kieffer, Ph.D., as the new Chief Operating Officer and has begun a search for Dr. Luly's successor to guide Enanta's next phase of growth.
BlackRock reports a passive stake above 5% in Enanta (ENTA).
BlackRock Portfolio Management LLC has reported a passive stake of 5.4% in Enanta Pharmaceuticals Inc. (ENTA), holding 1,560,091 common shares as of September 30, 2026. The filing indicates BlackRock has sole voting power over 1,461,051 shares and sole dispositive power over 1,560,091 shares. This disclosure reflects the holdings of specific BlackRock business units and affiliates, excluding others whose holdings are disaggregated.
Enanta Starts Phase 2b/3 RSV Trial, Eyes 2027 Data
Enanta Pharmaceuticals has dosed the first patient in its global Phase 2b/3 RESOLVE trial for zelicapavir, an antiviral treatment for RSV in high-risk adults. The study aims to evaluate symptom resolution and hospitalization rates, building on encouraging results from an earlier Phase 2 study. Enanta anticipates releasing topline Phase 2b results for RESOLVE in 2027, alongside data from its pediatric LOTUS trial, as it works towards potential regulatory approval for zelicapavir.
Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
Enanta Pharmaceuticals has initiated the RESOLVE Phase 2b/3 clinical trial for zelicapavir, an investigational treatment for Respiratory Syncytial Virus (RSV), by dosing its first patient. This global study aims to evaluate the drug's efficacy and safety in high-risk adult outpatients, with topline data from the Phase 2b portion anticipated in 2027. Zelicapavir, an N-protein inhibitor, holds potential as a first-in-disease antiviral therapy for RSV, a significant cause of illness, especially among older adults and those with underlying health conditions.
Enanta Pharmaceuticals starts late-stage RSV trial with 2027 data due
Enanta Pharmaceuticals has initiated a late-stage trial for its oral RSV treatment, zelicapavir, dosing the first patient in the RESOLVE study. The Phase 2b portion will enroll at least 200 high-risk adults, with results anticipated in 2027, focusing on symptom recovery and hospitalization. This trial aims to confirm the treatment's effect size and build upon earlier findings that suggested a benefit in symptom resolution for high-risk subgroups.
Enanta Pharmaceuticals, Inc. Estimates – NASDAQ:ENTA
This page provides financial estimates for Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) on TradingView. It allows users to explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
Enanta Pharmaceuticals, Inc. Estimates – MUN:9EP
This page on TradingView provides financial data and analyst estimates for Enanta Pharmaceuticals, Inc. (MUN:9EP). Users can explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform also offers tools for visualizing trends over time for the pharmaceutical company.
ENTA: Enanta Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas
This article provides an overview of Enanta Pharmaceuticals Inc. (ENTA), including its current stock price, market capitalization, and fundamental data. It highlights the company's focus on developing small molecule drugs for viral infections and liver diseases, and mentions upcoming presentations of data for its RSV treatment, Zelicapavir. The sentiment around ENTA is predominantly bullish, with recent news on earnings and clinical trial data.
Enanta announces October 22 RSV data presentation for Enanta Pharmaceuticals stock
Enanta Pharmaceuticals (NASDAQ: ENTA) will present clinical data for its zelicapavir RSV program on October 22, 2026. The presentation will cover symptom resolution, hospitalization, and viral load in high-risk adults from a Phase 2 trial. The company's stock was trading at EUR 10.45 on October 20, 2026, and its market capitalization was USD 342.5 million.
H.C. Wainwright keeps USD 20.00 target for Enanta Pharmaceuticals stock
H.C. Wainwright has reiterated its Buy rating and USD 20.00 price target for Enanta Pharmaceuticals (ENTA), representing an 80.18% upside from its current Nasdaq price of USD 11.10. The company's next earnings report is scheduled for November 16, 2026. Enanta Pharmaceuticals specializes in developing small-molecule treatments for viral and immunological diseases.
Wall Street Zen cuts Enanta Pharmaceuticals stock to Sell. Consensus target is USD 19.00.
Wall Street Zen has downgraded Enanta Pharmaceuticals (ENTA) stock from Hold to Sell, maintaining a consensus target of USD 19.00. The company reported a fiscal third-quarter revenue of USD 14.36 million and a net loss of USD 19.50 million. The stock is currently trading near its 52-week low, with its next earnings report expected on November 16, 2026.
Wall Street Zen cuts Enanta Pharmaceuticals stock to Sell. Consensus target is USD 19.00.
Wall Street Zen has downgraded Enanta Pharmaceuticals (ENTA) from Hold to Sell, although the consensus target price remains at USD 19.00. This comes after Enanta reported a fiscal third-quarter revenue of USD 14.36 million, a 16.32% drop from the previous quarter, and a net loss of USD 19.50 million. The company's stock was trading at EUR 10.25, and its Nasdaq quote was USD 11.45, near its 52-week low.
Enanta Pharmaceuticals, Inc. (ENTA) Stock Price, News, Quote & History
Enanta Pharmaceuticals, Inc. (ENTA) stock closed at $11.10, down 3.23%, on October 16, 2026. The biotechnology company focuses on discovering and developing small molecule drugs for virology and immunology, with a pipeline including treatments for HBV, RSV, human coronaviruses, and atopic dermatitis. Analysts have an average 1-year target estimate of $21.83 for the stock.
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
Enanta Pharmaceuticals (NASDAQ:ENTA) announced it will present data for its investigational respiratory syncytial virus (RSV) treatment, zelicapavir, at IDWeek™ 2026. The presentation will detail results from a Phase 2 trial showing zelicapavir decreased time to RSV symptom resolution, hospitalization, and viral load in high-risk adults. Enanta is a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections and immunological diseases.
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
Enanta Pharmaceuticals announced it will present data for zelicapavir, its oral, once-daily N-protein inhibitor for respiratory syncytial virus (RSV), at IDWeek™ 2026. The presentation will detail results from a Phase 2 trial in high-risk adults, showing zelicapavir decreases time to RSV symptom resolution, hospitalization, and viral load. The company, a clinical-stage biotechnology firm, focuses on developing small molecule drugs for viral infections and immunological diseases.
Wall Street Zen upgrades Enanta Pharmaceuticals stock to Hold
Wall Street Zen has upgraded Enanta Pharmaceuticals (ENTA) stock from Sell to Hold after the company posted an adjusted loss of USD 0.67 per share and revenue of USD 14.36 million in its fiscal third quarter, missing analyst consensus estimates. Despite the earnings miss, the stock remained unchanged at EUR 11.05 on October 8, 2026, on the Lang & Schwarz exchange. HC Wainwright previously reissued a Buy rating with a USD 20.00 price objective.
Enanta Pharmaceuticals stock fell 2.78 percent on October 5
Enanta Pharmaceuticals stock dropped by 2.78% on October 5, trading at USD 12.60. This decline follows the company's weak fiscal third-quarter results, which showed revenue of USD 14.36 million, below consensus estimates, and a consolidated net loss of USD 19.5 million. Despite the financial performance, analysts maintain a "Moderate Buy" consensus with an average price target of USD 19.00, valuing the company based on its clinical pipeline progress rather than current profitability.
Enanta Pharmaceuticals Inc (9EP.SG) Analyst insights, Price targets and Recommendations
This article provides analyst insights, price targets, and recommendations for Enanta Pharmaceuticals Inc (9EP.SG). It lists several reiterations of "Buy" ratings from HC Wainwright & Co., an initiation of "Overweight" from JP Morgan, and a "Buy" maintenance from WestPark Capital, spanning from late 2025 to late 2026. The stock was trading at 11.20 EUR, down 1.75% at the close on October 5th.
Enanta Pharmaceuticals stock gains 4.48 percent to EUR 11.65
Enanta Pharmaceuticals (ENTA) saw its stock price rise by 4.48% to EUR 11.65 at Lang & Schwarz on September 30, 2026, despite missing fiscal Q3 revenue estimates by $2.40 million. Analysts maintain a "Moderate Buy" consensus with an average 12-month target of $21.00, significantly above the current price. The company's focus on RSV programs and royalty income are key factors for investors, while the stock remains below its yearly high.
Enanta Pharmaceuticals to Participate in September Investor Conferences
Enanta Pharmaceuticals (NASDAQ: ENTA) announced its participation in two upcoming investor conferences in September. Jay R. Luly, Ph.D., President and CEO, will present at the H.C. Wainwright Global Investment Conference and the Morgan Stanley Global Healthcare Conference. This will allow investors to hear updates on the company's progress and pipeline.
Enanta Pharmaceuticals stock falls 1.25 percent to USD 11.85
Enanta Pharmaceuticals stock declined by 1.25% to USD 11.85 on September 25, 2026, after its fiscal Q3 revenue of USD 14.36 million missed analyst estimates. Despite the revenue miss, analysts maintain a "Moderate Buy" consensus with an average 12-month price target of USD 21.00, suggesting a significant upside. The company's pipeline, particularly RSV treatments, is highlighted as a future catalyst.
How Enanta Pharmaceuticals Inc. (ENTA) Affects Rotational Strategy Timing
This article analyzes Enanta Pharmaceuticals Inc. (ENTA) using AI models to provide trading strategies. It highlights weak near and mid-term sentiment but a strong long-term outlook, with a significant risk-reward setup. The analysis includes specific entry, target, and stop-loss levels for position, momentum breakout, and risk hedging strategies.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of "Moderate Buy" from Brokerages
Enanta Pharmaceuticals (NASDAQ:ENTA) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month target price of $21.00. Despite recent financial results falling short of expectations, institutional investors maintain high ownership, holding nearly 95% of ENTA shares. The company's stock recently opened at $12.00, having a market cap of $349.50 million.
Enanta Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright
H.C. Wainwright has reiterated a Buy rating and a $20.00 price target for Enanta Pharmaceuticals (NASDAQ: ENTA) following positive Phase 3 trial results from Celldex for a competing chronic spontaneous urticaria treatment. Enanta's oral KIT inhibitor, EDP-978, is seen as a significant near-term catalyst, with Phase 1 data expected in Q4 2026. This comes as Enanta recently reported fiscal third-quarter results below analyst expectations, primarily due to decreased royalty revenue.
Enanta Pharmaceuticals stock trades at USD 12.11
Enanta Pharmaceuticals (ENTA) stock traded at USD 12.11 on September 22, 2026, marking a 0.74 percent decline. The company's investment case is closely tied to its research programs and potential commercial milestones within the small-cap biotechnology sector. The market capitalization figure for Prothena Corporation plc was mistakenly included on the source page but is not relevant to Enanta.
Enanta Pharmaceuticals to Participate in September Investor Conferences
Enanta Pharmaceuticals, a clinical-stage biotechnology company, announced its participation in two investor conferences in September 2026: the Baird 2026 Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference. Management representatives will hold fireside chats at both events, with live webcasts and replays available on the company's website. Enanta focuses on developing small molecule drugs for viral infections and immunological diseases, with existing revenue from its hepatitis C drug, glecaprevir (MAVYRET/MAVIRET), developed with AbbVie.
Enanta Pharmaceuticals to Participate in September 2026 Investor Conferences
Enanta Pharmaceuticals, Inc. announced that its management will participate in two investor conferences in September 2026: the Baird 2026 Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference. Live webcasts and replays of these fireside chats will be available on the "Events and Presentations" section of Enanta's investor website. Enanta is a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections and immunological diseases.
Deep Track Capital, LP Trims Enanta Pharmaceuticals Inc (ENTA) S
Deep Track Capital, LP significantly reduced its stake in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by selling over 512,000 shares, decreasing its position by 26.20%. This move reflects a reassessment of Enanta, which is currently deemed "Significantly Overvalued" with a GF Value of $7.98 against a trading price of $13.14. The biotechnology company faces financial challenges, weak profitability, and growth metrics, prompting caution from institutional investors despite some recent price momentum.
Enanta Pharmceuticals Number of Employees 2026 | Employee Count & Headcount Data
Enanta Pharmaceuticals, Inc. (ENTA) had approximately 116 employees worldwide as of March 2026, marking a 27.6% decline from 160 employees in 2023. The company, headquartered in Watertown, Massachusetts, is not actively hiring, with zero active job postings in 2026. Its workforce is primarily concentrated in North America, and the average employee salary is $186,022.
Enanta Pharmaceuticals (ENTA) trims losses, funds pipeline into 2029
Enanta Pharmaceuticals (ENTA) reported narrowed net losses and expects its current cash and retained royalties to fund operations into fiscal 2029. The company's Q2 2026 royalty revenue decreased due to lower HCV sales, but R&D and general administrative expenses also declined. Enanta is advancing its RSV and immunology pipeline, including initiating registrational and pediatric clinical trials for zelicapavir and progressing other immunology programs.
Enanta Pharmaceuticals (Nasdaq:ENTA) - Stock Analysis
This Simply Wall St analysis provides a detailed overview of Enanta Pharmaceuticals (ENTA), a biotechnology company specializing in small molecule drugs. The report covers the company's valuation, future growth prospects (revenue forecast to grow 21.99% annually), past performance, financial health, and dividend policy, noting it is currently unprofitable but analysts expect stock price growth. It also includes market data such as share price history, volatility, and comparison against industry and market returns.
Enanta Pharmaceuticals (ENTA) Stock Faces Revenue Slip And Wider Losses
Enanta Pharmaceuticals (ENTA) experienced a 2.1% stock slip after reporting a Q3 loss with basic earnings per share at -$0.67 and a wider net loss of $19.50 million. While loss per share improved year-over-year, revenue declined from $18.31 million to $14.36 million, raising concerns about commercial cash flow and the company's ability to support its R&D pipeline amid continued losses and shareholder dilution. Investors are advised to consider the financing and execution risks associated with the company's early to mid-stage portfolio.
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot
Enanta Pharmaceuticals Inc. reported a fiscal third-quarter loss of $19.5 million, or 67 cents per share. The biotechnology company generated $14.4 million in revenue during the period. This financial snapshot was generated by Automated Insights using data from Zacks Investment Research.
Enanta Pharma misses Q3 estimates on lower royalty revenue
Enanta Pharmaceuticals missed its Q3 earnings and revenue estimates, reporting an adjusted EPS of -$0.67 against an expected -$0.50, and revenue of $14.4 million, short of the $17.4 million forecast. The shortfall was primarily due to lower royalty revenue from AbbVie’s hepatitis C virus regimen MAVYRET/MAVIRET. Despite the financial miss, Enanta highlighted progress in its RSV and immunology programs, with a Phase 2b pediatric trial underway for zelicapavir and a registrational trial expected to start in Q4 2026.
Press Release: Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2026
Enanta Pharmaceuticals announced its financial results for the fiscal third quarter ended June 30, 2026. The report details the company's financial performance during this period.
Enanta Pharma reports $19.5 million Q3 loss, advances RSV pipeline
Enanta Pharmaceuticals reported a net loss of $19.5 million for Q3 FY26, with revenue dropping 21% year-over-year to $14.4 million, missing analyst estimates. Despite financial setbacks, the company advanced its RSV pipeline, initiating the LOTUS pediatric trial and preparing for the RESOLVE adult trial. Enanta maintains a strong cash position of $211.5 million, providing financial runway into fiscal 2029.
Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Misses Expectations By $0.16 EPS
Enanta Pharmaceuticals (NASDAQ:ENTA) reported a quarterly loss of $0.67 per share, missing analyst estimates by $0.16. The biotechnology company also showed negative return on equity and net margin. Despite the earnings miss, the stock rose 0.3% during Monday trading, and institutional investors hold a significant portion of the company's shares.
Enanta Pharma misses Q3 estimates on lower royalty revenue By Investing.com
Enanta Pharmaceuticals reported third-quarter results that fell short of analyst expectations, with adjusted earnings per share of -$0.67 and revenue of $14.4 million, missing estimates of -$0.50 and $17.4 million, respectively. This underperformance was primarily due to lower royalty revenue from AbbVie’s hepatitis C virus regimen MAVYRET/MAVIRET. Despite the financial miss, Enanta highlighted progress in its RSV and immunology programs, with topline data for a Phase 2b pediatric trial expected in 2027 and a registrational Phase 2b/3 trial for high-risk adults on track for Q4 2026.
Enanta Fiscal Q3 2026 Earnings: Higher Royalty-Related Interest Expense Widens Net Loss
Enanta Pharmaceuticals reported a 21.6% decline in fiscal Q3 2026 revenue to $14.4 million due to lower MAVYRET/MAVIRET royalties. Despite narrowed operating losses from reduced clinical trial spending, the net loss widened to $19.5 million because of increased royalty-related interest expenses. The company holds $211.5 million in cash and marketable securities, expected to fund operations through fiscal 2029, and is focusing on key clinical trials and managing patent litigation risks.